Automata Technologies Limited

Based in the UK, Automata Technologies Limited develops innovative lab automation solutions, with a focus on enhancing laboratory workflows through their proprietary LINQ platform. Automata Technologies Limited specializes in lab automation solutions. Founded in 2015 by Alberto Di Cagno and Mostafa ElSayed, the company is headquartered in London, UK. In January 2026, Automata Technologies Limited raised USD 45 million in series C funding led by Dimension, with participation from Octopus Investments, Entrepreneur First, Danaher, and Tru Arrow Partners.

Automata Technologies specializes in lab automation solutions, primarily through its flagship product, LINQ. LINQ is a fully integrated platform designed to streamline laboratory workflows, enabling users to design complex experiments without the need for coding, utilizing a node-based Workflow Canvas. The platform includes features such as a Python SDK for customizable control, a Run Manager for real-time workflow tracking, and the ability to execute multiple workflows concurrently. LINQ can integrate with existing lab software and hardware, supporting a wide array of laboratory applications, including genomics, cell biology, and analytical chemistry.

The company serves a diverse clientele, including renowned institutions such as The Royal Marsden NHS Foundation Trust and The Francis Crick Institute, across geographic markets in the United Kingdom and the United States. Automata Technologies generates revenue primarily through the sale of its LINQ platform and associated services, which may include subscriptions to its cloud-based solutions and licensing agreements for its software. Transactions typically involve businesses in the life sciences sector that require automation of laboratory processes, thus enhancing operational efficiency and data management. Customers may opt for customized packages based on their specific needs, which can include tailored integrations with their existing systems and ongoing support services.

The pricing structure is aligned with the complexity and scale of the automation solutions deployed, with various plans available to accommodate different laboratory sizes and requirements, ensuring flexibility for its clients. The company plans to utilize the January 2026 funding to grow customer deployments, expand globally, and develop its next data and experimentation platform.